Our 13 Aug 2015 08:26
VENN royalties should be generating some cash....
RNs today
The consideration for this transaction will be GBP210,000, to be satisfied by new ordinary shares in the share capital of Venn calculated in accordance with the Disposal Agreement, a royalty of 7.5% on the gross sales of LabSkin(TM) for 3 years from date of acquisition, and a royalty of 25% on the future sale of or out-licence agreements for SYN1113.